Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Calcif Tissue Int. 2018 Jan 30;102(6):666–670. doi: 10.1007/s00223-017-0382-0

Fig. 1.

Fig. 1

A Area under curve for TmP/GFR during Visit 1 (left panel) and Visit 4, for patients treated with nasal calcitonin (red line) or placebo nasal spray (blue line). B Area under the curve for FGF23 during Visit 1 (left panel) or Visit 4 (right panel), for patients treated with nasal calcitonin (red line) or placebo nasal spray (blue line). C Area under the curve for 1,25 dihydroxyvitamin D during Visit 1 (left panel) or Visit 4 (right panel) for patients treated with nasal calcitonin (red line) or placebo (blue line). In all panels, data are presented as area under the curve for Least-Squares Means. (Color figure online)